Find information on thousands of medical conditions and prescription drugs.

Carvedilol

Carvedilol (Coreg®) is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). In addition to blocking both β1 and β2 type adrenoreceptors, carvedilol also displays α1-adrenergic antagonism as well, which confers the added benefit of reducing blood pressure through vasodilation. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

More importantly, carvedilol also has a minimal potential for "inverse agonism", or the deactivation of an activated receptor. This is important to CHF sufferers since inverse agonism causes negative chronotropic and inotropic effects. Essentially, carvedilol does not decrease the rate or strength of the hearts contractions as much as other beta blocking medications. CHF often significantly reduces how well the heart pumps, so any medication that further weakens the rate or strength of contractions is undesireable, therefore making carvedilol a better treatment than a beta blocker with stronger inverse agonism (such as propranolol).

On January 10, 2006, GlaxoSmithKline announced to pharmicists and physicans that there will be a limited availability of Coreg. This is due to documentation procedures with the manufacturer. It is not known when will Coreg will become broadly available. Patients who are taking Coreg should consult their healthcare professional about what actions they should take due to the shortage.

Read more at Wikipedia.org


[List your site here Free!]


Role of carvedilol and digoxin in heart failure
From American Family Physician, 7/15/04 by Karl E. Miller

In the treatment of heart failure and atrial fibrillation, digoxin has been a longstanding option. It is standard therapy in patients with heart failure and atrial fibrillation, but it is inadequate at rate control in these patients during exercise or times of increased sympathetic tone. Multiple studies have shown the benefit of beta-blocker therapy in the treatment of patients with heart failure. In addition, beta blockers have been shown to improve ventricular rate control in atrial fibrillation alone or in combination with digoxin. Despite these studies, no information demonstrates that beta blockers alone or in combination with digoxin improve outcomes in patients with heart failure and persistent atrial fibrillation. Khand and associates evaluated the use of digoxin, carvedilol, and their combination in the treatment of patients with heart failure and persistent atrial fibrillation.

The trial was a randomized, double-blind, placebo-controlled study of patients who met the standard criteria for heart failure and persistent atrial fibrillation for more then one month. All patients who entered the trial were taking digoxin. In phase 1 of the study, digoxin alone was compared with the combination of carvedilol and digoxin for four months. In phase 2, digoxin was withdrawn in a double-blinded fashion. Patients were assessed at the start of the study and at the end of each phase. Primary outcome measurements included assessment of left ventricular function, ventricular rate control, symptoms, and exercise tolerance.

There were 47 patients who participated in the study. The combination of digoxin and carvedilol, when compared with digoxin alone, provided a significantly lower ventricular rate on 24-hour monitoring and during submaximal exercise. In addition, combination therapy provided significantly better symptom control and improved left ventricular function compared with digoxin alone. When patients were changed to carvedilol alone, their mean ventricular rate rose, and the left ventricular ejection fraction declined. There was no difference in the six-minute walk distance between treatment arms.

The authors conclude that the combination of digoxin and carvedilol in the treatment of patients with heart failure and persistent atrial fibrillation is superior to either medication alone. They add that the combination provides better left ventricular function and ventricular rate control. In patients who were taking the combination, left ventricular function and rate control deteriorated after digoxin withdrawal. This study is the first to demonstrate the added benefit of digoxin in patients who are receiving beta-blocker therapy.

KARL E. MILLER, M.D.

Khand AU, et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol December 3, 2003;42:1944-51.

COPYRIGHT 2004 American Academy of Family Physicians
COPYRIGHT 2004 Gale Group

Return to Carvedilol
Home Contact Resources Exchange Links ebay